187 related articles for article (PubMed ID: 35573364)
1. Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.
Olivares JM; Fagiolini A
Front Psychiatry; 2022; 13():877867. PubMed ID: 35573364
[TBL] [Abstract][Full Text] [Related]
2. Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study.
Olivares JM; González-Pinto A; Páramo M;
Eur Psychiatry; 2021 Apr; 64(1):e40. PubMed ID: 33840396
[TBL] [Abstract][Full Text] [Related]
3. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data.
Waters HC; Stellhorn R; Touya M; Fitzgerald H; Bhattacharjee S; Citrome L
J Med Econ; 2023; 26(1):316-325. PubMed ID: 36780296
[TBL] [Abstract][Full Text] [Related]
4. Treatment persistence with aripiprazole once monthly: a 4-year follow-up.
Fagiolini A; Aguglia E; Ballerini A; Callista G; Carpiniello B; Clerici M; Corrivetti G; Cuomo A; De Fazio P; De Filippis S; De Giorgi S; Goracci A; La Barbera D; Mencacci C; Montagnani G; Pigato G; Vannucchi J; Vita A
Ann Gen Psychiatry; 2022 Sep; 21(1):39. PubMed ID: 36175924
[TBL] [Abstract][Full Text] [Related]
5. Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan.
Iwata N; Inagaki A; Sano H; Niidome K; Kojima Y; Yamada S
Adv Ther; 2020 Jul; 37(7):3324-3336. PubMed ID: 32500455
[TBL] [Abstract][Full Text] [Related]
6. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
[TBL] [Abstract][Full Text] [Related]
7. Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study.
Pae CU; Han C; Bahk WM; Lee SJ; Patkar AA; Masand PS
Clin Psychopharmacol Neurosci; 2021 May; 19(2):233-242. PubMed ID: 33888652
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study.
Pae CU; Han C; Bahk WM; Lee SJ; Patkar AA; Masand PS
Clin Psychopharmacol Neurosci; 2020 Feb; 18(1):153-158. PubMed ID: 31958916
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies.
Schöttle D; Clerzius G; Janetzky W; Oluboka O; Roy MA; Therrien F; Wiedemann K
Eur Psychiatry; 2022 Jul; 65(1):e42. PubMed ID: 35855645
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study.
Schöttle D; Janetzky W; Luedecke D; Beck E; Correll CU; Wiedemann K
BMC Psychiatry; 2018 Nov; 18(1):365. PubMed ID: 30428862
[TBL] [Abstract][Full Text] [Related]
11. BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study).
Schöttle D; Janetzky W; Therrien F; Wiedemann K
BMC Psychiatry; 2023 Mar; 23(1):162. PubMed ID: 36918846
[TBL] [Abstract][Full Text] [Related]
12. Initiation of aripiprazole once-monthly in patients with schizophrenia.
Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.
Xiao L; Zhao Q; Li AN; Sun J; Wu B; Wang L; Zhang H; Zhang R; Li K; Xu X; Liu T; Zhang W; Xie S; Xu X; Tan Y; Zhang K; Zhang H; Guan N; Xian M; Uki M; Wang G
Psychopharmacology (Berl); 2022 Jan; 239(1):243-251. PubMed ID: 34989824
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
[TBL] [Abstract][Full Text] [Related]
15. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies.
Madera JJ; Such P; Zhao C; Baker RA
Neuropsychiatr Dis Treat; 2019; 15():1593-1604. PubMed ID: 31354275
[No Abstract] [Full Text] [Related]
17. Adherence, Tolerability and Effective Doses of Aripiprazole Once-monthly in the Long-term Treatment of Patients with Severe Schizophrenia.
Fernández-Miranda JJ; Díaz-Fernández S; López-Muñoz F
Curr Pharm Des; 2021; 27(39):4078-4085. PubMed ID: 34218772
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
19. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.
Naber D; Baker RA; Eramo A; Forray C; Hansen K; Sapin C; Peters-Strickland T; Nylander AG; Hertel P; Nitschky Schmidt S; Loze JY; Potkin SG
Schizophr Res; 2018 Feb; 192():205-210. PubMed ID: 28433498
[TBL] [Abstract][Full Text] [Related]
20. A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-Onset Schizophrenia.
Such P; Bøg M; Kabra MS; Jørgensen KT; de Jong-Laird AC
Prim Care Companion CNS Disord; 2021 Sep; 23(5):. PubMed ID: 34592798
[No Abstract] [Full Text] [Related]
[Next] [New Search]
